| Drug General Information |
| Drug ID |
D0F6EZ
|
| Former ID |
DNC007902
|
| Drug Name |
(4-guanidino-benzyl)-carbamic acid benzyl ester
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H18N4O2
|
| Canonical SMILES |
C1=CC=C(C=C1)COC(=O)NCC2=CC=C(C=C2)N=C(N)N
|
| InChI |
1S/C16H18N4O2/c17-15(18)20-14-8-6-12(7-9-14)10-19-16(21)22-11-13-4-2-1-3-5-13/h1-9H,10-11H2,(H,19,21)(H4,17,18,20)
|
| InChIKey |
NXBMHZOVQPKBKA-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Urokinase-type plasminogen activator |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Complement and coagulation cascades
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
PANTHER Pathway
|
Blood coagulation
|
|
Plasminogen activating cascade
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Beta1 integrin cell surface interactions
|
|
E2F transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
Beta2 integrin cell surface interactions
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
FGF signaling pathway
|
|
Reactome
|
Dissolution of Fibrin Clot
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
Complement and Coagulation Cascades
|
|
Endochondral Ossification
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
Blood Clotting Cascade
|
|
Dissolution of Fibrin Clot
|
|
Osteopontin Signaling
|
| References |
| REF 1 | J Med Chem. 2007 Dec 27;50(26):6638-46. Epub 2007 Dec 1.Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. |
|---|
